The Board of Directors of Sagent Pharmaceuticals has announced that Jeffrey Yordon, Chairman and Chief Executive Officer, has informed the Board of his decision to retire from the company.
What does it cost to miss a deadline? For the company that makes the prescription painkiller...
Dow Chemical is breaking off a significant portion of its chlorine operations in a deal valued...
Recipharm AB and Adroit Science AB have announced the formation of a new strategic collaboration...
A new report expects the market value for sepsis treatments to increase more than thirteen-fold between 2016 and 2021 following the launch of a new sepsis-specific drug.
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon.
The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.
Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.
AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
There are many nuances that require a more focused approach to risk identification and project management for the “new” manufacturing facilities implementing Single-use Systems (SUS).
The Supreme Court is taking up a challenge by industry groups and Republican-led states that want to roll back Obama administration environmental rules aimed at reducing power plant emissions of mercury and other hazardous air pollutants that contribute to respiratory illnesses, birth defects and developmental problems in children.
Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.
House Republicans quietly deepened recommended budget savings from the government's chief health care program for the poor by about $140 billion in recent weeks to offset part of the cost of higher payments to doctors who treat Medicare patients, according to officials familiar with the tradeoff.
BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
The agency said its tracking of claims by cosmetics companies during recent years indicated a proliferation in drugs claims--defined by the FDA as "intended to treat or prevent disease, or change the body’s structure or functions"--on product packaging and in web advertising.
The World Health Organization denied that politics swayed the decision to declare an international emergency over the spread of the Ebola virus last year, despite evidence senior staffers repeatedly discussed the diplomatic and economic fallout of such a move.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.
A recent report found the pharmaceutical industry increased its contribution to the global economy between 2006 and 2012.
Over nearly two decades, inventions and products licensed by academic institutions contributed more than $1 trillion to the U.S. economy, according to a recent report from the Biotechnology Industry Organization.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Coronado Biosciences has announced the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology.
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. The transaction is expected to close on 31 March 2015.
Mergers and acquisitions in the pharmaceutical and biotechnology sectors set a record in 2014, according to a report by Evaluate Ltd.
Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics--most notably Singulair, Advair and Symbicort--would allow generic versions to curb market growth.
A judge has dismissed a lawsuit by Herbalife shareholders who claimed that the business structure and marketing practices of the weight loss and nutritional supplements company violated the law and that they lost money in what amounts to a pyramid scheme.
- Page 1